Press Releases

Press Releases

November 5, 2019
Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM) Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) with Data Expected in First Half of 2020 Entered into Exclusive Collaboration with Notch Therapeutics
November 5, 2019
Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales SOUTH SAN FRANCISCO,
September 3, 2019
SOUTH SAN FRANCISCO, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Morgan
August 7, 2019
ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Advances with Five Clinical Trial Sites Open Investigational New Drug (IND) Application Cleared by the U.S. Food & Drug Administration ( FDA ) for ALLO-715 Targeting BCMA for the Treatment of Patients
Displaying 1 - 10 of 23
Print Page
E-mail Alerts
RSS
Investor Contacts